Novo Nordisk A/S (NVO) Stock Forecast & Price Target

$88.06 +4.33 (+5.16%)

Closing price 02/21/2025 03:59 PM Eastern

Extended Trading

$88.10 +0.04 (+0.05%)

As of 02/21/2025 07:59 PM Eastern

Novo Nordisk A/S - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 8 Analyst Ratings

Sell
0

Hold
2

Buy
6

Based on 8 Wall Street analysts who have issued ratings for Novo Nordisk A/S in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 8 analysts, 2 have given a hold rating, 5 have given a buy rating, and 1 has given a strong buy rating for NVO.

Consensus Price Target

$145.25
64.93% Upside

According to the 8 analysts' twelve-month price targets for Novo Nordisk A/S, the average price target is $145.25. The highest price target for NVO is $160.00, while the lowest price target for NVO is $105.00. The average price target represents a forecasted upside of 64.93% from the current price of $88.07.

Get the Latest News and Ratings for NVO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Novo Nordisk A/S and its competitors.

NVO Analyst Ratings Over Time

Type	Current Forecast 2/23/24 to 2/22/25	1 Month Ago 1/24/24 to 1/23/25	3 Months Ago 11/25/23 to 11/24/24	1 Year Ago 2/23/23 to 2/23/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)
Hold	2 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$145.25	$140.20	$144.50	$121.25
Forecasted Upside	64.93% Upside	72.33% Upside	37.54% Upside	-1.75% Downside
Consensus Rating	Moderate Buy	Buy	Moderate Buy	Moderate Buy

NVO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NVO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Novo Nordisk A/S Stock vs. The Competition

Type	Novo Nordisk A/S	Medical Companies	S&P 500
Consensus Rating Score	2.88	2.82	2.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	64.93% Upside	29,427.70% Upside	14.37% Upside
News Sentiment Rating	Positive News See Recent NVO News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
2/12/2025	Morgan Stanley 3 of 5 stars		Initiated Coverage	Equal Weight
1/8/2025	UBS Group 4 of 5 stars	J. Walton Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell ➝ Buy
1/6/2025	Sanford C. Bernstein 3 of 5 stars	W. Kapadia Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Market Perform
12/23/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$156.00 ➝ $105.00	+23.53%
12/2/2024	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Parkes Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
11/6/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$160.00 ➝ $160.00	+49.39%
6/10/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$125.00 ➝ $160.00	+13.09%
5/30/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$156.00	+17.58%
12/4/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$105.00 ➝ $115.00	+14.19%
8/11/2023	DNB Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
Get the Latest News and Ratings for NVO and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Novo Nordisk A/S and its competitors with MarketBeat's FREE daily newsletter.
7/14/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy
4/13/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 01:22 AM ET.

Should I Buy Novo Nordisk A/S Stock? NVO Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, February 17, 2025. Please send any questions or comments about these Novo Nordisk A/S pros and cons to contact@marketbeat.com.

Novo Nordisk A/S
Bull Case

Here are some ways that investors could benefit from investing in Novo Nordisk:

Strong Financial Performance: Novo Nordisk reported earnings per share (EPS) of $0.91, exceeding analysts' expectations of $0.88, indicating robust profitability and effective cost management.
High Return on Equity: The company boasts a return on equity of 84.68%, showcasing its ability to generate significant profit from shareholders' equity, which is a positive indicator for potential investors.
Market Capitalization: With a market cap of $349.75 billion, Novo Nordisk is a large and stable company, which often attracts institutional investors and provides a sense of security for individual investors.
Current Stock Price: As of the latest trading session, Novo Nordisk's stock price is $77.94, which may present a buying opportunity for investors looking for value in a well-established company.
Recent Stake Increases: Institutional investors, such as Pittenger & Anderson Inc., have recently increased their stakes in Novo Nordisk, indicating confidence in the company's future performance and potential for growth.

Novo Nordisk A/S
Bear Case

Investors should be bearish about investing in Novo Nordisk for these reasons:

Stock Price Volatility: The stock has experienced fluctuations, with a 12-month high of $148.15 and a low of $77.82, which may indicate potential risks for investors concerned about price stability.
Debt-to-Equity Ratio: Novo Nordisk has a debt-to-equity ratio of 0.62, which, while not excessively high, suggests that the company does carry some debt, potentially impacting its financial flexibility.
Recent Stake Reductions: Some institutional investors, like James Investment Research Inc., have reduced their holdings by 42.5%, which could signal a lack of confidence in the stock's short-term performance.
Market Competition: The pharmaceutical industry is highly competitive, and Novo Nordisk faces challenges from other companies in the diabetes and obesity treatment markets, which could affect its market share and profitability.
Potential Regulatory Risks: As a pharmaceutical company, Novo Nordisk is subject to regulatory scrutiny, and any changes in regulations or approval processes could impact its operations and financial results.

NVO Forecast - Frequently Asked Questions

: According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Novo Nordisk A/S is $145.25, with a high forecast of $160.00 and a low forecast of $105.00.
: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last twelve months. There are currently 2 hold ratings, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NVO shares.
: According to analysts, Novo Nordisk A/S's stock has a predicted upside of 64.93% based on their 12-month stock forecasts.
: Over the previous 90 days, Novo Nordisk A/S's stock had 3 upgrades by analysts.
: Novo Nordisk A/S has been rated by research analysts at BMO Capital Markets, BNP Paribas, Morgan Stanley, Sanford C. Bernstein, and UBS Group in the past 90 days.
: Analysts like Novo Nordisk A/S more than other "medical" companies. The consensus rating score for Novo Nordisk A/S is 2.88 while the average consensus rating score for "medical" companies is 2.82. Learn more on how NVO compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:NVO) was last updated on 2/22/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novo Nordisk A/S (NVO) Stock Forecast & Price Target